Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

BioBeats Transitions from Stress App to Well-Being Platform

XTALKS VITALS NEWS

Digital Health

The evolution of the startup is being spurred by Microsoft’s decision to withdraw their wearable fitness tracker, the Microsoft Band, from the market.

Share this!

October 28, 2016 | by Sarah Hand, M.Sc.

UK-based digital health company, BioBeats, is making changes to their stress monitoring app to accommodate for other factors of well-being. The evolution of the startup is being spurred by Microsoft’s decision to withdraw their wearable fitness tracker, the Microsoft Band, from the market.

BioBeats used the Microsoft Band as the hardware to run their app. The fitness tracker was distributed to 560 UK employees of the French bank, BNP Paribas, for a pilot study on workplace-related stress.

While that study – which collected over 60 gigabytes of data – was completed in August, neither BioBeats nor the academics who lead the study have released any of the study’s findings. However, BioBeats did comment in a press release that “scientific findings include perceived/actual stress, links between stress and ruminators, and the outcome of breathing as an intervention.”

According to BioBeats CEO, David Plans, the company may be losing access to the Microsoft Band, but they are gaining a partnership with Google. They are in the early stages of developing this collaboration, and currently choosing their hardware and software.



BioBeats is also conducting larger studies, one of which involves tracking 41,000 people in a non-controlled environment. These types of studies should help the digital health company further refine its AI.

“We focus on predictive analytics and the intelligence behind it,” said Plans. The company’s apps use artificial intelligence in the cloud, which Plans says look for “instances of well-being.”

With the BNP Paribas study, the company set their sights on identifying central nervous system issues. One of the activities the study participants were asked to do was to breath in specific ways in order to induce stress.

This stress research has helped BioBeats to identify markers for cardiovascular health, but Plans said the company is now branching out into other areas. Their next challenges is to detect and model markers of neuropathy.

“It’s turning into an overall well-being platform,” said Plans. “As our machine learning gets more sophisticated, it becomes of more use to large employers that have a lot of [private medical insurance] claims.”

Because the app does not claim to be diagnostic, it is not required to seek regulatory clearance by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Instead, the app simply points to markers of potential health issues, which can be forwarded along to healthcare professionals.

The company expects to launch a new version of the BioBeats app sometime next month, with new wearables due out next year. In 2017, they also plan to try to enter the US market with their mobile health app.


Keywords: Digital Health, Stress, Cardiovascular Health


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.